Literature DB >> 29344631

A Brief Exposure-Based Treatment vs Cognitive Processing Therapy for Posttraumatic Stress Disorder: A Randomized Noninferiority Clinical Trial.

Denise M Sloan1,2, Brian P Marx1,2, Daniel J Lee1, Patricia A Resick3.   

Abstract

Importance: Written exposure therapy (WET), a 5-session intervention, has been shown to efficaciously treat posttraumatic stress disorder (PTSD). However, this treatment has not yet been directly compared with a first-line PTSD treatment such as cognitive processing therapy (CPT). Objective: To determine if WET is noninferior to CPT in patients with PTSD. Design, Setting, and Participants: In this randomized clinical trial conducted at a Veterans Affairs medical facility between February 28, 2013, and November 6, 2016, 126 veteran and nonveteran adults were randomized to either WET or CPT. Inclusion criteria were a primary diagnosis of PTSD and stable medication therapy. Exclusion criteria included current psychotherapy for PTSD, high risk of suicide, diagnosis of psychosis, and unstable bipolar illness. Analysis was performed on an intent-to-treat basis. Interventions: Participants assigned to CPT (n = 63) received 12 sessions and participants assigned to WET (n = 63) received 5 sessions. The CPT protocol that includes written accounts was delivered individually in 60-minute weekly sessions. The first WET session requires 60 minutes while the remaining 4 sessions require 40 minutes. Main Outcomes and Measures: The primary outcome was the total score on the Clinician-Administered PTSD Scale for DSM-5; noninferiority was defined by a score of 10 points. Blinded evaluations were conducted at baseline and 6, 12, 24, and 36 weeks after the first treatment session. Treatment dropout was also examined.
Results: For the 126 participants (66 men and 60 women; mean [SD] age, 43.9 [14.6] years), improvements in PTSD symptoms in the WET condition were noninferior to improvements in the CPT condition at each of the assessment periods. The largest difference between treatments was observed at the 24-week assessment (mean difference, 4.31 points; 95% CI, -1.37 to 9.99). There were significantly fewer dropouts in the WET vs CPT condition (4 [6.4%] vs 25 [39.7%]; χ21 = 12.84, Cramer V = 0.40). Conclusions and Relevance: Although WET involves fewer sessions, it was noninferior to CPT in reducing symptoms of PTSD. The findings suggest that WET is an efficacious and efficient PTSD treatment that may reduce attrition and transcend previously observed barriers to PTSD treatment for both patients and providers. Trial Registration: clinicaltrials.gov Identifier: NCT01800773.

Entities:  

Mesh:

Year:  2018        PMID: 29344631      PMCID: PMC5843538          DOI: 10.1001/jamapsychiatry.2017.4249

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  21 in total

1.  Are 60-minute prolonged exposure sessions with 20-minute imaginal exposure to traumatic memories sufficient to successfully treat PTSD? A randomized noninferiority clinical trial.

Authors:  Nitsa Nacasch; Jonathan D Huppert; Yi-Jen Su; Yogev Kivity; Yula Dinshtein; Rebecca Yeh; Edna B Foa
Journal:  Behav Ther       Date:  2014-12-13

2.  Brief treatment for PTSD: A non-inferiority trial.

Authors:  Denise M Sloan; Brian P Marx; Patricia A Resick
Journal:  Contemp Clin Trials       Date:  2016-04-11       Impact factor: 2.226

3.  Treatment initiation and dropout from prolonged exposure and cognitive processing therapy in a VA outpatient clinic.

Authors:  Shannon M Kehle-Forbes; Laura A Meis; Michele R Spoont; Melissa A Polusny
Journal:  Psychol Trauma       Date:  2015-06-29

4.  The effect of imaginal exposure length on outcome of treatment for PTSD.

Authors:  Agnes van Minnen; Edna B Foa
Journal:  J Trauma Stress       Date:  2006-08

5.  Utilization of evidence-based psychotherapies in Veterans Affairs posttraumatic stress disorder outpatient clinics.

Authors:  Erin P Finley; Hector A Garcia; Norma S Ketchum; Donald D McGeary; Cindy A McGeary; Shannon Wiltsey Stirman; Alan L Peterson
Journal:  Psychol Serv       Date:  2014-11-24

6.  Evaluation of an implementation model: a national investigation of VA residential programs.

Authors:  Joan M Cook; Stephanie Dinnen; James C Coyne; Richard Thompson; Vanessa Simiola; Josef Ruzek; Paula P Schnurr
Journal:  Adm Policy Ment Health       Date:  2015-03

7.  Use of evidence-based treatment for posttraumatic stress disorder in Army behavioral healthcare.

Authors:  Joshua E Wilk; Joyce C West; Farifteh F Duffy; Richard K Herrell; Donald S Rae; Charles W Hoge
Journal:  Psychiatry       Date:  2013       Impact factor: 2.458

8.  Meta-analysis of dropout in treatments for posttraumatic stress disorder.

Authors:  Zac E Imel; Kevin Laska; Matthew Jakupcak; Tracy L Simpson
Journal:  J Consult Clin Psychol       Date:  2013-01-21

9.  Manualized therapy for PTSD: flexing the structure of cognitive processing therapy.

Authors:  Tara E Galovski; Leah M Blain; Juliette M Mott; Lisa Elwood; Timothy Houle
Journal:  J Consult Clin Psychol       Date:  2012-10-29

10.  TELEMEDICINE VERSUS IN-PERSON DELIVERY OF COGNITIVE PROCESSING THERAPY FOR WOMEN WITH POSTTRAUMATIC STRESS DISORDER: A RANDOMIZED NONINFERIORITY TRIAL.

Authors:  Leslie A Morland; Margaret-Anne Mackintosh; Craig S Rosen; Emy Willis; Patricia Resick; Kathleen Chard; B Christopher Frueh
Journal:  Depress Anxiety       Date:  2015-08-03       Impact factor: 6.505

View more
  37 in total

Review 1.  Management of Post-traumatic Stress Disorder in Veterans and Military Service Members: A Review of Pharmacologic and Psychotherapeutic Interventions Since 2016.

Authors:  Bret A Moore; Lynette Pujol; Scott Waltman; David S Shearer
Journal:  Curr Psychiatry Rep       Date:  2021-01-06       Impact factor: 5.285

2.  Early interventions to prevent posttraumatic stress disorder symptoms in survivors of life-threatening medical events: A systematic review.

Authors:  Jeffrey L Birk; Jennifer A Sumner; Mytra Haerizadeh; Reuben Heyman-Kantor; Louise Falzon; Christopher Gonzalez; Liliya Gershengoren; Peter Shapiro; Donald Edmondson; Ian M Kronish
Journal:  J Anxiety Disord       Date:  2019-03-20

3.  Brief online interventions for LGBTQ young adult mental and behavioral health: A randomized controlled trial in a high-stigma, low-resource context.

Authors:  John E Pachankis; Stacey L Williams; Kriti Behari; Sarah Job; Erin M McConocha; Stephenie R Chaudoir
Journal:  J Consult Clin Psychol       Date:  2020-05

4.  A Randomized Controlled Trial of Group Cognitive Behavioral Treatment for Veterans Diagnosed With Chronic Posttraumatic Stress Disorder.

Authors:  Denise M Sloan; William Unger; Daniel J Lee; J Gayle Beck
Journal:  J Trauma Stress       Date:  2018-11-29

5.  Peer delivery of a brief cognitive-behavioral treatment for posttraumatic stress disorder: A hybrid effectiveness-implementation pilot study.

Authors:  Ashley M Smith; Kaylee Stewart; Tithi Baul; Sarah E Valentine
Journal:  J Clin Psychol       Date:  2020-07-06

6.  Psychometric properties of the Posttraumatic Avoidance Behaviour Questionnaire among a treatment-seeking adult sample.

Authors:  Rachel Shor; Daniel J Lee; Johanna Thompson-Hollands; Denise M Sloan
Journal:  Psychol Trauma       Date:  2021-08-16

7.  Long-term treatment gains of a brief exposure-based treatment for PTSD.

Authors:  Johanna Thompson-Hollands; Brian P Marx; Daniel J Lee; Patricia A Resick; Denise M Sloan
Journal:  Depress Anxiety       Date:  2018-08-24       Impact factor: 6.505

8.  Predictors of Dropout in Cognitive Processing Therapy for PTSD: An Examination of Trauma Narrative Content.

Authors:  Elizabeth Alpert; Adele M Hayes; J Ben Barnes; Denise M Sloan
Journal:  Behav Ther       Date:  2019-11-26

9.  Brief novel therapies for PTSD: Written Exposure Therapy.

Authors:  Johanna Thompson-Hollands; Brian P Marx; Denise M Sloan
Journal:  Curr Treat Options Psychiatry       Date:  2019-06-05

10.  Written Exposure Therapy vs Cognitive Processing Therapy-Reply.

Authors:  Denise M Sloan; Brian P Marx; Daniel J Lee
Journal:  JAMA Psychiatry       Date:  2018-07-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.